bioRxivImmunology
Anamnestic Humoral Correlates of Immunity Across SARS-CoV-2 Variants of Concern
R. McNamara, J. S. Maron, H. L. Bertera, J. Boucau, V. Roy, A. K. Barczak, The Positives Study Staff, N. Franko, J. Z. Li, J. S. McLellan, M. Siedner, J. E. Lemieux, H. Chu, G. Alter
Abstract
While immune correlates against SARS-CoV-2 are typically defined at peak immunogenicity following vaccination, immunologic responses that expand selectively during the anamnestic response following infection can provide mechanistic and detailed insights into the immune mechanisms of protection. Moreover, whether anamnestic correlates are conserved across VoCs, including the Delta and more distant Omicron variant of concern (VoC), remains unclear. To define the anamnestic correlates of immunity, across VOCs, we deeply profiled the humoral immune response in individuals recently infected with either the Delta or Omicron VoC. While limited acute N-terminal domain and RBD-specific immune expansion was observed following breakthrough, a significant immunodominant expansion of opsinophagocytic Spike-specific antibody responses focused largely on the conserved S2-domain of SARS-CoV-2 was observed 1 week after breakthrough infection. This S2-specific functional humoral response continued to evolve over 2-3 weeks following both Delta and Omicron breakthrough infection, targeting multiple VoCs and common coronaviruses. These responses were focused largely on the fusion peptide 2 and heptad repeat 1, both associated with enhanced rates of viral clearance. Taken together, our results point to a critical role of highly conserved, functional S2-specific responses in the control of SARS-CoV-2 infection, across VOCs, and thus humoral response linked to virus attenuation can guide next-generation generation vaccine boosting approaches to confer broad protection against future SARS-CoV-2 VoCs.
- organism: human
- assay: proteomics
- research focus: host-pathogen & immune response
- research focus: drug response / drug discovery
- research focus: benchmarking
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Vaccine-breakthrough infection by the SARS-CoV-2 Omicron variant elicits broadly cross-reactive immune responses
R. Zhou, K. K.-W. To, … Z. Chen·bioRxiv·Dec 27, 2021
- Anti-spike antibody response to natural infection with SARS-CoV-2 and its activity against emerging variants
C.-P. Chen, K.-Y. A. Huang, … S.-H. Cheng·bioRxiv·Mar 7, 2022
- Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, beta, delta, and omicron variants
A. Banerjee, J. Lew, … D. Falzarano·bioRxiv·Jan 13, 2022
- Prior vaccination enhances immune responses during SARS-CoV-2 breakthrough infection with early activation of memory T cells followed by production of potent neutralizing antibodies
M. M. Painter, T. S. Johnston, … E. J. Wherry·bioRxiv·Feb 5, 2023
- Extensive neutralization against SARS-CoV-2 variants elicited by Omicron-specific subunit vaccine booster
- Broad human and animal coronavirus neutralisation by SARS-CoV-2 S2-targeted vaccination
K. Ng, N. Faulkner, … G. Kassiotis·bioRxiv·Nov 30, 2021